Clinical guidelines and policies
This section provides information for health professionals regarding clinical guidelines associated with the use of blood components and/or products.
Clinical guidelines
-
NZBS Policy on the Provision of CMV Antibody Negative Blood Components (111P067) (PDF, 36 KB)
-
NZBS Policy on the Use of Fresh Blood (111P074) (PDF, 36 KB)
-
Use of Rh-D Immunoglobulin During Pregnancy and the Post Partum Period (111G130) (PDF, 66 KB)
RhD Immunoglobulin is commonly known as Anti-D Immunoglobulin. It is used to reduce the risk for an RhD negative woman being immunised by red blood cells from a fetus or baby during a pregnancy or after childbirth. See also Blood Group Antibodies & Haemolytic Disease of the Newborn - A Basic Guide for Lead Maternity Providers (111I101) - Nonconforming blood products are those that, at the point of issue for clinical use, have not completed all of the mandatory testing and processing requirements. The supply of these products is outside our usual supply arrangements and NZBS is unable to take responsibility for the quality or safety of the product in its non-conforming state. This policy outlines the strict terms under which nonconforming products will be released.
-
Guidelines for the Management of Patients Refractory to Platelets (111G002) (PDF, 46 KB)
The purpose of this document is to define how patients who are truly refractory to platelet transfusions should be managed. It is based on reviews of the literature and currently accepted practice. -
Blood Component Support of Rh(D) Negative Individuals (111P032) (PDF, 68 KB)
-
The Provision of Blood for Cardiopulmonary Bypass (CPB) Surgery (111P046) (PDF, 27 KB)
-
Policy for Collection and Transfusion of Granulocytes (111P049) (PDF, 71 KB)
-
Guidelines for the Use of Therapeutic Plasma Exchange (TPE) in Renal Disease (111G081) (PDF, 57 KB)
-
These guidelines, published by the Australian and New Zealand Society Of Blood Transfusion (ANZSBT), cover important procedural issues, equipment dosimetry and maintenance, and clinical indications for providing X-ray or gamma-irradiated blood components.
These blood components are provided to avoid a risk of graft-versus-host disease in a recipient who has a severe inherited or acquired cell mediated immune deficiency, or where the recipient is a close family member of a selected donor.
You may need to download Adobe Reader to view the PDF files. It is available free from the Adobe site.
